Two Seas Capital LP Makes New $2.74 Million Investment in PAVmed Inc. $PAVM

Two Seas Capital LP purchased a new stake in PAVmed Inc. (NASDAQ:PAVM) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 461,539 shares of the company’s stock, valued at approximately $2,742,000. Two Seas Capital LP owned 46.15% of PAVmed at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Jane Street Group LLC increased its holdings in shares of PAVmed by 392.9% in the second quarter. Jane Street Group LLC now owns 52,676 shares of the company’s stock worth $32,000 after purchasing an additional 41,990 shares during the period. Geode Capital Management LLC raised its position in shares of PAVmed by 74.8% in the fourth quarter. Geode Capital Management LLC now owns 168,832 shares of the company’s stock worth $40,000 after buying an additional 72,258 shares in the last quarter. Finally, BlackRock Inc. bought a new stake in PAVmed during the second quarter valued at $102,000. 19.93% of the stock is currently owned by hedge funds and other institutional investors.

PAVmed Price Performance

PAVM opened at $5.18 on Friday. The business’s fifty day simple moving average is $5.19 and its 200 day simple moving average is $7.46. PAVmed Inc. has a 52 week low of $3.85 and a 52 week high of $28.44. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.98. The stock has a market cap of $41.44 million, a PE ratio of -0.32 and a beta of 0.54.

Wall Street Analysts Forecast Growth

PAVM has been the subject of several recent analyst reports. Ascendiant Capital Markets reduced their target price on PAVmed from $65.00 to $56.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Weiss Ratings cut PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $56.00.

PAVmed Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.